Drug Trial Radar · NCT04442503
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Jun 8, 2020
Primary completion
Mar 15, 2022
Study completion Apr 12, 2022
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jun 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
Conditions
- Depression, Postpartum
Interventions
SAGE-217Drug
SAGE-217 oral capsules.
PlaceboDrug
SAGE-217 matched-placebo oral capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Time frame: Baseline and Day 15
Locations
82 sites in 3 countries. Site status is shown where the registry gives one.
Sage Investigational Site
Scottsdale, Arizona
Sage Investigational Site
Bentonville, Arkansas
Sage Investigational Site
Anaheim, California
Sage Investigational Site
Bellflower, California
Sage Investigational Site
Beverly Hills, California
Sage Investigational Site
Costa Mesa, California
Sage Investigational Site
Imperial, California
Sage Investigational Site
Lemon Grove, California
Sage Investigational Site
Norwalk, California
Sage Investigational Site
Oceanside, California
Sage Investigational Site
Orange, California
Sage Investigational Site
Orange, California
Sage Investigational Site
Redlands, California
Sage Investigational Site
San Bernardino, California
Sage Investigational Site
Sherman Oaks, California
Sage Investigational Site
Torrance, California
Sage Investigational Site
Aurora, Colorado
Sage Investigational Site
Norwich, Connecticut
Sage Investigational Site
Boynton Beach, Florida
Sage Investigational Site
Hialeah, Florida
Sage Investigational Site
Jacksonville, Florida
Sage Investigational Site
Miami, Florida
Sage Investigational Site
Miami Springs, Florida
Sage Investigational Site
Miramar, Florida
Sage Investigational Site
Orlando, Florida
Sage Investigational Site
Orlando, Florida
Sage Investigational Site
Pensacola, Florida
Sage Investigational Site
Pinellas Park, Florida
Sage Investigational Site
Pompano Beach, Florida
Sage Investigational Site
Alpharetta, Georgia
Sage Investigational Site
Atlanta, Georgia
Sage Investigational Site
Decatur, Georgia
Sage Investigational Site
Savannah, Georgia
Sage Investigational Site
Idaho Falls, Idaho
Sage Investigational Site
Hoffman Estates, Illinois
Sage Investigational Site
Lincolnwood, Illinois
Sage Investigational Site
Wichita, Kansas
Sage Investigational Site
New Orleans, Louisiana
Sage Investigational Site
Boston, Massachusetts
Sage Investigational Site
Detroit, Michigan
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.